APA (7th ed.) Citation

RA, S., DF, F., L, L., AY, C., P, S., R, Y., . . . DM, W. (2016). A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science translational medicine, 8(341), 341ra76. https://doi.org/10.1126/scitranslmed.aad3744

Chicago Style (17th ed.) Citation

RA, Scott, et al. "A Genomic Approach to Therapeutic Target Validation Identifies a Glucose-lowering GLP1R Variant Protective for Coronary Heart Disease." Science Translational Medicine 8, no. 341 (2016): 341ra76. https://doi.org/10.1126/scitranslmed.aad3744.

MLA (9th ed.) Citation

RA, Scott, et al. "A Genomic Approach to Therapeutic Target Validation Identifies a Glucose-lowering GLP1R Variant Protective for Coronary Heart Disease." Science Translational Medicine, vol. 8, no. 341, 2016, p. 341ra76, https://doi.org/10.1126/scitranslmed.aad3744.